JP Morgan Chase
BCAX

JP Morgan Chase’s Bicara Therapeutics BCAX Stock Holding History

JP Morgan Chase’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.38M Buy
177,408
+160,561
+953% +$2.76M ﹤0.01% 3682
2025
Q4 		$284K Sell
16,847
-8,088
-32% -$138K ﹤0.01% 5347
2025
Q3 		$394K Sell
24,935
-2,523
-9% -$28.2K ﹤0.01% 5166
2025
Q2 		$255K Buy
27,458
+5,664
+26% +$67.5K ﹤0.01% 5119
2025
Q1 		$284K Sell
21,794
-42,946
-66% -$570K ﹤0.01% 5082
2024
Q4 		$1.13M Buy
64,740
+64,010
+8,768% +$1.33M ﹤0.01% 4549
2024
Q3 		$18.6K Buy
+730
New +$18.6K ﹤0.01% 6250

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $112M AUM 91.52% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

JP Morgan Chase's BCAX Position: Q1 2026 in Review

JP Morgan Chase increased its Bicara Therapeutics (BCAX) stake by 953% in Q1 2026, buying an estimated $2.76M and bringing the position to 177,408 shares worth $3.38M. The position accounts for ﹤0.01% of the portfolio, ranked #3682.

JP Morgan Chase first reported a position in BCAX in Q3 2024 and has held it in 7 quarters since. 146 funds tracked by Wall St. Rank hold BCAX as of Q1 2026.

  • JP Morgan Chase held 177,408 shares of Bicara Therapeutics worth $3.38M as of Q1 2026.
  • JP Morgan Chase bought 160,561 Bicara Therapeutics shares in Q1 2026, an estimated $2.76M.
  • Bicara Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #3682 holding.
  • JP Morgan Chase first reported a position in Bicara Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • 146 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.